-
Uddannelse
Find uddannelse
Studievejledning
Kvalitet
- Forskning
-
Samarbejde
Virksomheder
Kommuner og regioner
Gymnasier
Myndigheder
-
Om AU
Organisation
Kontakt
Om AU
- Organisation
- Ledelse
- Strategi
- AU i tal
- AU's historie
- Internationalt samarbejde
- Bæredygtighed
- Campus 2.0
- Diversitet og ligestilling
- Ledige stillinger
- Presse
- Kontakt
The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820097/pdf/jir.2021.0106.pdf
Forlagets udgivne version
DOI
- https://doi.org/10.1089/jir.2021.0106
Forlagets udgivne version
- Michelle Møhlenberg
- Ida Monrad
- Line K. Vibholm ,
- Stine S.F. Nielsen
- Giacomo Schmidt Frattari ,
- Mariane Høgsbjerg Schleimann
- Rikke Olesen
- Mads Kjolby
- Jesper Damsgaard Gunst
- Ole Schmeltz Søgaard
- Thomas R. O'Brien, National Cancer Institute, Rockville, Maryland ,
- Martin Tolstrup
- Rune Hartmann
Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Interferon and Cytokine Research |
| Vol/bind | 41 |
| Nummer | 11 |
| Sider (fra-til) | 407-414 |
| Antal sider | 8 |
| ISSN | 1079-9907 |
| DOI | |
| Status | Udgivet - nov. 2021 |
Bibliografisk note
Funding Information:
The funding source had no role in the study design, collection, analysis, and interpretation of data, writing of the article, or the decision to submit the article for publication. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
Se relationer på Aarhus Universitet Citationsformater
ID: 227520542